{"url_path":"/sec/orka/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-055769-index.html","accession_number":"0001213900-26-055769","cik":"0000907654","ticker":"ORKA","issuer_name":"Oruka Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/907654/0001213900-26-055769-index.html","primary_entity_key":"0000907654","primary_entity_name":"Oruka Therapeutics, Inc."},"word_count":215,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\n*Trading Plans*\n\n \n\nDuring the quarter ended March 31, 2026, no director\nor Section 16 officer adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case,\nas defined in Item 408(a) of Regulation S-K), except as disclosed below.\n\n \n\nOn February 11, 2026, Arjun Agarwal, our Senior Vice President –\nFinance and Treasurer, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the\nsale of shares of our common stock over a period ending upon the earlier of when all shares under the plan are sold, or February 26, 2027,\nsubject to certain conditions. This plan covers the sale of up to (i) 97,965 shares (ii) 100% of net vested RSUs from gross RSU grants\nof up to 4,375 shares and (iii) 100% of shares purchased pursuant to the ESPP on June 8, 2026 and December 8, 2026.\n\n \n\nOn February 19, 2026, Carl Dambkowski, a director\nin our company, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of\nup to 140,000 shares of our common stock over a period ending upon the earlier of when all shares under the plan are sold, or May 31,\n2027, subject to certain conditions."}